Locatelli, F.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Fellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 414

Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial

Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P. (1999) · Journal of Cardiovascular Pharmacology

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 77

Individualised treatment effects of corticosteroids in IgA nephropathy

Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 2